Human Genome Sciences HGSI

GSK ( GSK ) ammends the conditions of its $2.6B tender offer for Human Genome ( HGSI ), requiring that the latter redeem or invalidate its poison pill. Post your comment!

… GSK ) was in the news for a move to acquire Human Genome Sciences (NASDAQ: HGSI ), its partner of up to twenty years for ..... you follow the news, you will remember that Human Genome Sciences rejected the offer saying that the $13 dollar …

By Mel Daris : Sanofi ( SNY ) has not reported a lot of good news lately. The company plans to shut down a plant in Newcastle, and a drug that it has been working on has not received the approval for which the company had hoped. The company's factory in Tyneside, will not be saved and the 450 ...

… billion offer was announced, Human Genome Sciences ( HGSI ) made its intentions known that ..... long-term ramifications of it, HGSI hired Goldman Sachs and Credit ..... respectability to the overture to HGSI . The response by HGSI was not …

Human Genome Sciences ( HGSI ) announces adoption of short-term stockholder rights plan, with a term of one year. Also says its board of directors unanimously …

By Scott Matusow : In part one of this three part article, I mentioned Antares Pharma ( AIS ) and iBio ( IBIO ) as two companies that could reward patient investors with a long term 'jackpot' reward. In this article, I will focus on one company I feel investors should look at for both short term,

By Stock Croc : Recently, Pfizer ( PFE ) attempted to survive the patent expiration of Lipitor by spending enormous amounts of money on marketing the drug, although cheaper alternatives are now available. This is an interesting move on the drug company's part as I feel that the strategy of pumping

By Kapitall : Interested in the growth prospects of the biotech industry? For a closer look at stocks of the biotech sector with positive market sentiment, we ran a screen. We began by screening the biotech industry for stocks currently rallying above their 20-day, 50-day, and 200-day moving ...